Velarion · Company Intelligence
Compensation Brief
Fiscal year 2024 · Filings through 2026-10-01

Exact Sciences (EXAS)

CEO Kevin Conroy was paid $15,539,378 in fiscal year 2024, ↓ down 3.6% from fiscal year 2023, the 59th percentile of its disclosed peer group (SEC filing 0001124140-25-000034 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$15,539,378 ↓
Kevin Conroy total, FY2024
59th
CEO pay percentile vs peers
109:1
CEO-to-median pay ratio
93.58%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

01

Summary Compensation Table — fiscal year 2024

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Kevin Conroy$1,083,368$0$13,496,138$0$712,329$0$247,543$15,539,378
Chairman, President and Chief Executive Officer
Aaron Bloomer431,868600,0006,002,8370136,662015,4217,186,788
Executive Vice President and Chief Financial Officer
Jacob Orville618,00003,581,2980202,812031,0824,433,192
Executive Vice President and General Manager, Screening
Brian Baranick600,40003,581,2980196,980020,9904,399,668
Executive Vice President and General Manager, Precision Oncology
Everett Cunningham315,50303,820,4280005,7234,141,654
Former Executive Vice President and Former Chief Commercial Officer
Jeffrey Elliott392,1760273,1730002,556,0923,221,441
Former Executive Vice President and Former Chief Financial Officer
Sarah Condella509,00001,910,2130167,344058,9982,645,555
Executive Vice President, Human Resources

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Kevin Conroy$15,539,378$16,119,899$14,223,999↓ −580,521
Aaron Bloomer7,186,788———
Jacob Orville4,433,1923,668,3312,749,179↑ +764,861
Brian Baranick4,399,6683,574,009—↑ +825,659
Everett Cunningham4,141,6544,546,9665,176,570↓ −405,312
Jeffrey Elliott3,221,4414,077,6813,870,737↓ −856,240
Sarah Condella2,645,5553,058,6962,714,543↓ −413,141

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Exact Sciences's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper EXAS reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against EXAS
20 companies name EXAS as a compensation peer

The list of companies that name EXAS as a peer is temporarily unavailable — recheck shortly.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2024 total
D. Scott CowardDirector$333,892
Daniel LevangieIndependent Director$346,392
Freda Lewis-HallFormer director (through FY2024)—
James DoyleLead Independent Director$381,392
Katherine ZanottiIndependent Director$343,892
Kathleen SebeliusFormer director (through FY2024)$341,392
Leslie TriggIndependent Director—
Michael BarberIndependent Director$673,683
Paul ClancyIndependent Director$356,392
Pierre JacquetFormer director (through FY2024)—
Shacey PetrovicIndependent Director$338,892
Timothy ScannellFormer director (through FY2024)$111,364
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
D. Scott CowardDirector2025-06-12A5,398$0$0CommonForm 4 ↗
Daniel LevangieDirector2025-06-12A5,39800CommonForm 4 ↗
Shacey PetrovicDirector2025-06-12A5,39800CommonForm 4 ↗
Leslie TriggDirector2025-06-12A7,67000CommonForm 4 ↗
Kimberly PopovitsDirector2025-06-12A9,99400CommonForm 4 ↗
Michael BarberDirector2025-06-12A7,19700CommonForm 4 ↗
James DoyleDirector2025-06-12A5,39800CommonForm 4 ↗
Katherine ZanottiDirector2025-06-12A5,39800CommonForm 4 ↗
Paul ClancyDirector2025-06-12A5,39800CommonForm 4 ↗
Katherine ZanottiDirector2025-06-13D3,20753170,612CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-08-05D5,35000Derivative, Class A CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-08-05D2,71747127,237CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-08-05A5,35000CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-08-05A5,35000CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-08-05D5,35000Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-08-05D2,51547117,777CommonForm 4 ↗
James DoyleDirector2025-08-13D1,4854262,400CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-10-09D1,5006090,000CommonForm 4 ↗
James DoyleDirector2025-10-09D2,00060120,000CommonForm 4 ↗
Katherine ZanottiDirector2025-10-24D12,00065780,000CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-11-04D2,85870200,289CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-11-04D1,50070105,120CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-11-19D1,0007070,000CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-11-19D5,00075375,000CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23A9,41600CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2025-12-23D38,71500Derivative, Class A CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2025-12-23D10,8031021,099,961CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2025-12-23A24,38400CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2025-12-23D17,1511021,746,315CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2025-12-23A38,71500CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D7,12500Derivative, Class A CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D3,78000Derivative, Class A CommonForm 4 ↗
Dividend-equivalent accruals2025-12-23—1,648——1 insider, 1 accrual row
James HerriottSVP, General Counsel & Sec2025-12-23D7,118102724,755CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A15,14400CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D14,2351021,449,408CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A30,28700CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D4,644102472,852CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A9,88000CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D7,995102814,051CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A17,00900CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D3,447102350,974CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A7,33400CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D6,530102664,885CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A13,89300CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A7,12500CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D1,777102180,934CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A3,78000CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D77510278,911CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A1,64800CommonForm 4 ↗
Kevin ConroyDirector2025-12-23D155,41710215,824,559CommonForm 4 ↗
Kevin ConroyDirector2025-12-23A330,67400CommonForm 4 ↗
Kevin ConroyDirector2025-12-23D65,0141026,619,725CommonForm 4 ↗
Kevin ConroyDirector2025-12-23D115,11810211,721,315CommonForm 4 ↗
Kevin ConroyDirector2025-12-23A244,93100CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D23,81700Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D7,56000Derivative, Class A CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D10,4531021,064,324CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23A20,58400CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23A16,05100CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D14,6141021,487,997CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D7,539102767,621CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23A9,45000CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23A3,95500CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D14,84500Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D9,45000Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D3,95500Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D9,675102985,109CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23A20,58400CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D19,9861022,034,975CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23A42,52300CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D13,5271021,377,319CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D6,978102710,500CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23A14,84500CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23A9,45000CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23A3,95500CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23A11,87600CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23A42,52300CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23A14,84500CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D7,33400Derivative, Class A CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D13,89300Derivative, Class A CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D3,349102340,995CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D16,05100Derivative, Class A CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D9,45000Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23A34,01800CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23A8,00000CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D14,84500Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D16,05100Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D28,77900Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D4,426102450,655CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23A16,05100CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23A28,77900CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D4,442102452,284CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D1,859102189,283CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D7,544102768,130CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D3,95500Derivative, Class A CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D21,5941022,198,701CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D8,151102829,935CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23A28,77900CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D4,799102488,634CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D2,009102204,556CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D28,77900Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D11,87600Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D3,95500Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D3,760102382,843CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D11,1941021,139,773CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23A23,81700CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D3,554102361,868CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23A7,56000CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D1,859102189,283CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23A3,95500CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D5,582102568,359CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D15,9891021,628,000CommonForm 4 ↗
Kevin ConroyDirector2025-12-23A138,32600CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2025-12-23D24,38400Derivative, Class A CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-24D14,9381021,517,551CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-24A29,41600CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2026-02-25A28,06300Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-02-25A154,82900Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-02-25D6,196103640,976CommonForm 4 ↗
Kevin ConroyDirector2026-02-25A13,18100CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2026-02-25A20,32100Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2026-02-25A38,70700Derivative, Class A CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2026-02-25A28,06300Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-02-25A23,22400Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-02-27D3,90000Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-02-27D1,913103197,766CommonForm 4 ↗
Kevin ConroyDirector2026-02-27D27,78600Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-02-27D18,14300Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-02-27D13,0601031,348,445CommonForm 4 ↗
Kevin ConroyDirector2026-02-27D10,4191031,075,762CommonForm 4 ↗
Kevin ConroyDirector2026-02-27D8,528103880,516CommonForm 4 ↗
Kevin ConroyDirector2026-02-27A18,14300CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-02-27A3,900519,617CommonForm 4 ↗
Kevin ConroyDirector2026-02-27A27,78600CommonForm 4 ↗
Kevin ConroyDirector2026-02-27D22,16800Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-02-27A22,16800CommonForm 4 ↗
Michael BarberDirector2026-03-23D5,398——CommonForm 4 ↗
Paul ClancyDirector2026-03-23D5,398——CommonForm 4 ↗
Paul ClancyDirector2026-03-23D20,640——CommonForm 4 ↗
James DoyleDirector2026-03-23D5,398——CommonForm 4 ↗
James DoyleDirector2026-03-23D52,564——CommonForm 4 ↗
Kimberly PopovitsDirector2026-03-23D6,725——CommonForm 4 ↗
Katherine ZanottiDirector2026-03-23D5,398——CommonForm 4 ↗
Katherine ZanottiDirector2026-03-23D55,361——CommonForm 4 ↗
Shacey PetrovicDirector2026-03-23D5,398——CommonForm 4 ↗
D. Scott CowardDirector2026-03-23D4,175——Derivative, Class A CommonForm 4 ↗
D. Scott CowardDirector2026-03-23D5,398——CommonForm 4 ↗
D. Scott CowardDirector2026-03-23D52,164——CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2026-03-23D6,581——Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2026-03-23D1,774——CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2026-03-23A53,32300CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D154,829——Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D83,360——Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D18,143——Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D100,916——Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D34,110——Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D235,388——Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D86,750——CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D46,538——CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D29,061——CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-03-23D6,581——Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-03-23D191,891——CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2026-03-23D4,395——Derivative, Class A CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2026-03-23D417——CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2026-03-23D138,679——CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2026-03-23A89,91100CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2026-03-23D20,321——Derivative, Class A CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2026-03-23D2,861——Derivative, Class A CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2026-03-23D793——Derivative, Class A CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2026-03-23D1,762——CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2026-03-23D28,063——Derivative, Class A CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2026-03-23D137,195——CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2026-03-23A33,32100CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2026-03-23D28,063——Derivative, Class A CommonForm 4 ↗
Leslie TriggDirector2026-03-23D3,244——CommonForm 4 ↗
Shacey PetrovicDirector2026-03-23D16,406——CommonForm 4 ↗
D. Scott CowardDirector2026-03-23D12,875——Derivative, Class A CommonForm 4 ↗
D. Scott CowardDirector2026-03-23D4,694——CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2026-03-23D38,707——Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-03-23D23,224——Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-03-23A60,38900CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2026-03-23D68,195——CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2026-03-23D153,726——CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2026-03-23D795——CommonForm 4 ↗
Michael BarberDirector2026-03-23D7,42200Derivative, Class A CommonForm 4 ↗
Leslie TriggDirector2026-03-23D13,925——CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-03-23D7,790——Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-03-23D11,700——Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-03-23D21,948——Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-03-23D6,368——CommonForm 4 ↗
Kimberly PopovitsDirector2026-03-23D9,656——CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D44,336——Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D66,047——Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D117,427——CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D1,397,738——CommonForm 4 ↗
Kevin ConroyDirector2026-03-23A119,31200CommonForm 4 ↗
D. Scott CowardDirector2026-03-23D10,786——Derivative, Class A CommonForm 4 ↗
Michael BarberDirector2026-03-23D7,738——CommonForm 4 ↗
Shacey PetrovicDirector2026-03-23D7,095——CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 200 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
D. Scott CowardDirector2025-06-12A5,398$0$0CommonForm 4 ↗
Daniel LevangieDirector2025-06-12A5,39800CommonForm 4 ↗
Shacey PetrovicDirector2025-06-12A5,39800CommonForm 4 ↗
Leslie TriggDirector2025-06-12A7,67000CommonForm 4 ↗
Kimberly PopovitsDirector2025-06-12A9,99400CommonForm 4 ↗
Michael BarberDirector2025-06-12A7,19700CommonForm 4 ↗
James DoyleDirector2025-06-12A5,39800CommonForm 4 ↗
Katherine ZanottiDirector2025-06-12A5,39800CommonForm 4 ↗
Paul ClancyDirector2025-06-12A5,39800CommonForm 4 ↗
Katherine ZanottiDirector2025-06-13D3,20753170,612CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-08-05D5,35000Derivative, Class A CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-08-05D2,71747127,237CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-08-05A5,35000CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-08-05A5,35000CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-08-05D5,35000Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-08-05D2,51547117,777CommonForm 4 ↗
James DoyleDirector2025-08-13D1,4854262,400CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-10-09D1,5006090,000CommonForm 4 ↗
James DoyleDirector2025-10-09D2,00060120,000CommonForm 4 ↗
Katherine ZanottiDirector2025-10-24D12,00065780,000CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-11-04D2,85870200,289CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-11-04D1,50070105,120CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-11-19D1,0007070,000CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-11-19D5,00075375,000CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23A9,41600CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2025-12-23D38,71500Derivative, Class A CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2025-12-23D10,8031021,099,961CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2025-12-23A24,38400CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2025-12-23D17,1511021,746,315CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2025-12-23A38,71500CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D7,12500Derivative, Class A CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D3,78000Derivative, Class A CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D1,64800Derivative, Class A CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D7,118102724,755CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A15,14400CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D14,2351021,449,408CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A30,28700CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D4,644102472,852CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A9,88000CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D7,995102814,051CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A17,00900CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D3,447102350,974CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A7,33400CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D6,530102664,885CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A13,89300CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A7,12500CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D1,777102180,934CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A3,78000CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D77510278,911CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23A1,64800CommonForm 4 ↗
Kevin ConroyDirector2025-12-23D155,41710215,824,559CommonForm 4 ↗
Kevin ConroyDirector2025-12-23A330,67400CommonForm 4 ↗
Kevin ConroyDirector2025-12-23D65,0141026,619,725CommonForm 4 ↗
Kevin ConroyDirector2025-12-23D115,11810211,721,315CommonForm 4 ↗
Kevin ConroyDirector2025-12-23A244,93100CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D23,81700Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D7,56000Derivative, Class A CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D10,4531021,064,324CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23A20,58400CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23A16,05100CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D14,6141021,487,997CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D7,539102767,621CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23A9,45000CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23A3,95500CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D14,84500Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D9,45000Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D3,95500Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D9,675102985,109CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23A20,58400CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D19,9861022,034,975CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23A42,52300CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D13,5271021,377,319CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D6,978102710,500CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23A14,84500CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23A9,45000CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23A3,95500CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23A11,87600CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23A42,52300CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23A14,84500CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D7,33400Derivative, Class A CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D13,89300Derivative, Class A CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2025-12-23D3,349102340,995CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D16,05100Derivative, Class A CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D9,45000Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23A34,01800CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23A8,00000CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D14,84500Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D16,05100Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D28,77900Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D4,426102450,655CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23A16,05100CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23A28,77900CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D4,442102452,284CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D1,859102189,283CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2025-12-23D7,544102768,130CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D3,95500Derivative, Class A CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D21,5941022,198,701CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D8,151102829,935CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23A28,77900CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D4,799102488,634CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D2,009102204,556CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-23D28,77900Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D11,87600Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D3,95500Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D3,760102382,843CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D11,1941021,139,773CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23A23,81700CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D3,554102361,868CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23A7,56000CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D1,859102189,283CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23A3,95500CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D5,582102568,359CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2025-12-23D15,9891021,628,000CommonForm 4 ↗
Kevin ConroyDirector2025-12-23A138,32600CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2025-12-23D24,38400Derivative, Class A CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-24D14,9381021,517,551CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2025-12-24A29,41600CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2026-02-25A28,06300Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-02-25A154,82900Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-02-25D6,196103640,976CommonForm 4 ↗
Kevin ConroyDirector2026-02-25A13,18100CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2026-02-25A20,32100Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2026-02-25A38,70700Derivative, Class A CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2026-02-25A28,06300Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-02-25A23,22400Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-02-27D3,90000Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-02-27D1,913103197,766CommonForm 4 ↗
Kevin ConroyDirector2026-02-27D27,78600Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-02-27D18,14300Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-02-27D13,0601031,348,445CommonForm 4 ↗
Kevin ConroyDirector2026-02-27D10,4191031,075,762CommonForm 4 ↗
Kevin ConroyDirector2026-02-27D8,528103880,516CommonForm 4 ↗
Kevin ConroyDirector2026-02-27A18,14300CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-02-27A3,900519,617CommonForm 4 ↗
Kevin ConroyDirector2026-02-27A27,78600CommonForm 4 ↗
Kevin ConroyDirector2026-02-27D22,16800Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-02-27A22,16800CommonForm 4 ↗
Michael BarberDirector2026-03-23D5,398——CommonForm 4 ↗
Paul ClancyDirector2026-03-23D5,398——CommonForm 4 ↗
Paul ClancyDirector2026-03-23D20,640——CommonForm 4 ↗
James DoyleDirector2026-03-23D5,398——CommonForm 4 ↗
James DoyleDirector2026-03-23D52,564——CommonForm 4 ↗
Kimberly PopovitsDirector2026-03-23D6,725——CommonForm 4 ↗
Katherine ZanottiDirector2026-03-23D5,398——CommonForm 4 ↗
Katherine ZanottiDirector2026-03-23D55,361——CommonForm 4 ↗
Shacey PetrovicDirector2026-03-23D5,398——CommonForm 4 ↗
D. Scott CowardDirector2026-03-23D4,175——Derivative, Class A CommonForm 4 ↗
D. Scott CowardDirector2026-03-23D5,398——CommonForm 4 ↗
D. Scott CowardDirector2026-03-23D52,164——CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2026-03-23D6,581——Derivative, Class A CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2026-03-23D1,774——CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2026-03-23A53,32300CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D154,829——Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D83,360——Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D18,143——Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D100,916——Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D34,110——Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D235,388——Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D86,750——CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D46,538——CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D29,061——CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-03-23D6,581——Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-03-23D191,891——CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2026-03-23D4,395——Derivative, Class A CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2026-03-23D417——CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2026-03-23D138,679——CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2026-03-23A89,91100CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2026-03-23D20,321——Derivative, Class A CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2026-03-23D2,861——Derivative, Class A CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2026-03-23D793——Derivative, Class A CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2026-03-23D1,762——CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2026-03-23D28,063——Derivative, Class A CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2026-03-23D137,195——CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2026-03-23A33,32100CommonForm 4 ↗
Aaron BloomerEVP, Chief Financial Officer2026-03-23D28,063——Derivative, Class A CommonForm 4 ↗
Leslie TriggDirector2026-03-23D3,244——CommonForm 4 ↗
Shacey PetrovicDirector2026-03-23D16,406——CommonForm 4 ↗
D. Scott CowardDirector2026-03-23D12,875——Derivative, Class A CommonForm 4 ↗
D. Scott CowardDirector2026-03-23D4,694——CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2026-03-23D38,707——Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-03-23D23,224——Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-03-23A60,38900CommonForm 4 ↗
James HerriottSVP, General Counsel & Sec2026-03-23D68,195——CommonForm 4 ↗
Jacob OrvilleEVP, GM, Screening2026-03-23D153,726——CommonForm 4 ↗
Brian BaranickEVP, GM, Precision Oncology2026-03-23D795——CommonForm 4 ↗
Michael BarberDirector2026-03-23D7,42200Derivative, Class A CommonForm 4 ↗
Leslie TriggDirector2026-03-23D13,925——CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-03-23D7,790——Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-03-23D11,700——Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-03-23D21,948——Derivative, Class A CommonForm 4 ↗
Sarah CondellaEVP, Human Resources2026-03-23D6,368——CommonForm 4 ↗
Kimberly PopovitsDirector2026-03-23D9,656——CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D44,336——Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D66,047——Derivative, Class A CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D117,427——CommonForm 4 ↗
Kevin ConroyDirector2026-03-23D1,397,738——CommonForm 4 ↗
Kevin ConroyDirector2026-03-23A119,31200CommonForm 4 ↗
D. Scott CowardDirector2026-03-23D10,786——Derivative, Class A CommonForm 4 ↗
Michael BarberDirector2026-03-23D7,738——CommonForm 4 ↗
Shacey PetrovicDirector2026-03-23D7,095——CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2024

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Brian BaranickPSU2024-02-261,23719,792—44,533$1,249,469
Sarah CondellaPSU2024-02-2699015,834—35,627999,600
Kevin ConroyPSU2024-02-268,313133,006—299,2648,396,669
Jacob OrvillePSU2024-02-261,23719,792—44,5331,249,469
Jeffrey ElliottRSU2024-02-26——4,750—273,173
Aaron BloomerRSU2024-04-15——11,556—755,185
Aaron BloomerRSU2024-04-15——51,619—3,373,302
Sarah CondellaRSU2024-02-26——15,834—910,613
Everett CunninghamRSU2024-02-26——31,668—1,821,227
Jacob OrvilleRSU2024-02-26——19,793—1,138,295
Aaron BloomerPSU2024-04-151,63326,127—58,7841,874,351
Brian BaranickRSU2024-02-26——19,793—1,138,295
Brian BaranickRSU2024-08-05——21,401—1,193,534
Kevin ConroyRSU2024-02-26——88,671—5,099,469
Everett CunninghamPSU2024-02-261,97931,668—71,2531,999,201
Jacob OrvilleRSU2024-08-05——21,401—1,193,534
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Brian Baranick$2,331,829$1,249,469$034.9%
Sarah Condella910,613999,600052.3%
Kevin Conroy5,099,4698,396,669062.2%
Jacob Orville2,331,8291,249,469034.9%
Jeffrey Elliott273,173000.0%
Aaron Bloomer4,128,4871,874,351031.2%
Everett Cunningham1,821,2271,999,201052.3%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Kevin ConroyRSU54,429—$3,058,366
Brian BaranickRSU44,533—2,502,309
Sarah CondellaRSU35,627—2,001,881
Jacob OrvilleRSU2,248—126,315
Sarah CondellaRSU15,834—889,712
Kevin ConroyOption66,04744.37—
Brian BaranickRSU21,401—1,202,522
Sarah CondellaOption6,58198.18—
Jacob OrvilleOption6,58198.18—
Brian BaranickRSU1,729—97,153
Jacob OrvilleRSU44,533—2,502,309
Kevin ConroyRSU26,361—1,481,225
Jacob OrvilleRSU19,793—1,112,169
Kevin ConroyRSU299,264—16,815,644
Kevin ConroyOption34,11092.62—
Sarah CondellaOption7,79092.62—
Kevin ConroyRSU244,931—13,762,673
Sarah CondellaOption11,70044.37—
Kevin ConroyRSU88,671—4,982,423
Aaron BloomerRSU58,784—3,303,073
Aaron BloomerRSU51,619—2,900,472
Jacob OrvilleRSU42,523—2,389,367
Brian BaranickRSU42,523—2,389,367
Sarah CondellaRSU7,909—444,407
Sarah CondellaRSU34,018—1,911,471
Jacob OrvilleRSU21,401—1,202,522
Brian BaranickRSU19,793—1,112,169
Jacob OrvilleRSU14,175—796,493
Brian BaranickRSU14,175—796,493
Aaron BloomerRSU11,556—649,332
Kevin ConroyOption235,38821.68—
Sarah CondellaRSU11,340—637,195
Kevin ConroyRSU10,374—582,915
Jacob OrvilleRSU7,909—444,407
Brian BaranickRSU7,909—444,407
Jeffrey ElliottOption11,36192.62—
Jeffrey ElliottOption12,87598.18—
Sarah CondellaRSU2,248—126,315
Sarah CondellaOption21,94821.68—
Kevin ConroyOption66,72323.38—
Kevin ConroyOption100,91698.18—
Sarah CondellaOption3,9005.03—
05

Incentive-plan design — the Compensation Discussion & Analysis

The compensation program is designed to attract, motivate, and retain qualified executives by aligning their interests with long-term shareholder value creation. It emphasizes a pay-for-performance philosophy where a significant portion of compensation is variable and at-risk, tied to rigorous financial and operational performance targets and stock price performance.

CEO STI target (% of salary)140%
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-06-12140,371,2929,625,458441,07093.58%Passed
20242024-06-13131,505,67712,170,551284,27991.53%Passed
20232023-06-08125,242,81712,934,948407,21890.64%Passed
20222022-06-09127,608,5008,862,911304,68093.51%Passed
20212021-06-3087,736,32842,105,148374,05167.57%Passed
20202020-07-23103,318,5943,994,544697,88496.28%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-06-1293.58%a
20242024-06-1391.53%b
20232023-06-0890.64%c

a. Approved under the standard stated in the filing — “Abstentions will therefor have no effect on Proposal 1.”.

b. Approved under the standard stated in the filing — “Broker non-votes and abstentions are not counted as votes cast on any proposal considered at the Annual Meeting and, therefore, will have no effect on Proposals 1 and 3.”.

c. Approved under the standard stated in the filing — “Broker non-votes and abstentions are not counted as votes cast on any proposal considered at the Annual Meeting and, therefore, will have no effect on Proposals 1, 3, 4, and 6.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)109 : 1
CEO total compensation$15,539,378
Median employee compensation$142,608
08

Director compensation — fiscal year 2024

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Michael BarberIndependent · Audit and Finance · Innovation, Technology & Pipeline (Chair) · Newly elected$102,500$571,183———$673,683
James DoyleIndependent · Lead Independent Director · Corporate Governance and Nominating · Human Capital127,500253,892———381,392
Paul ClancyIndependent · Audit and Finance (Chair) · Corporate Governance and Nominating102,500253,892———356,392
Daniel LevangieIndependent · Audit and Finance · Human Capital92,500253,892———346,392
Katherine ZanottiIndependent · Human Capital (Chair)90,000253,892———343,892
Kathleen SebeliusIndependent · Departed during FY87,500253,892———341,392
Shacey PetrovicIndependent · Corporate Governance and Nominating (Chair)85,000253,892———338,892
D. Scott CowardEmployee director · Innovation, Technology & Pipeline80,000253,892———333,892
Timothy ScannellIndependent · Not standing for re-election · Departed during FY0111,364———111,364
Freda Lewis-HallIndependent · Human Capital · Not standing for re-election · Departed during FY00———0
Kimberly PopovitsIndependent · Human Capital · Innovation, Technology & Pipeline00———0
Kevin ConroyEmployee director · Board Chair—————0
Leslie TriggIndependent · Newly elected00———0
Pierre JacquetIndependent · Not standing for re-election · Departed during FY00———0
09

Board fee structure and ownership guideline

Annual cash retainer$70,000
Annual equity retainer$300,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)12,500 / 20,000 / 15,000
Stock ownership guideline$5
09b

Total cost of the board

ComponentFY2024
Cash retainers and fees$767,500
Equity awards (grant-date value)$2,459,791
All other compensation$0
Total cost of the board$3,227,291

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2024

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Exact Sciences names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Exact Sciences.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Seagen, Inc.2022David Epstein$190,385$14,815,386$42,381,246$0$57,460,546
2Incyte Corporation2025William Meury647,26027,509,6572,573,9981,300,00032,085,952
3BioMarin Pharmaceutical Inc.2025Alexander Hardy1,130,76916,833,6291,909,3101,644,50021,927,563
4Horizon Therapeutics Public Ltd Co2022Timothy Walbert1,292,72716,601,3050020,103,869
5Masimo Corporation2025Catherine Szyman850,04816,388,6931,399,9981,130,00019,797,140
6Align Technology, Inc.2025Joseph Hogan1,400,00016,556,87201,220,10019,193,988
7Insulet Corporation2025Ashley McEvoy729,80812,958,8502,999,9132,031,56218,858,968
8Edwards Lifesciences Corporation2025Bernard Zovighian1,192,5007,167,0246,499,1092,406,53717,454,255
9ResMed Inc.2026Michael Farrell1,272,8959,749,4683,249,9071,738,85716,201,649
10Hologic, Inc.2024Stephen MacMillan1,212,6289,141,4682,937,4771,990,41315,819,261
11Exact Sciences2024Kevin Conroy1,083,36813,496,1380712,32915,539,378
12Natera, Inc.2025Steven Chapman853,71012,979,55801,114,15114,957,319
13Alnylam Pharmaceuticals, Inc.2025Yvonne Greenstreet1,404,2005,512,5004,363,3803,562,50014,867,600
14IDEXX Laboratories, Inc.2025Jonathan Mazelsky1,150,0005,399,8815,400,0012,593,00014,580,122
15Agilent Technologies, Inc.2025Padraig McDonnell1,141,3458,169,8502,017,7591,436,80912,827,236
16Quidel Corporation2025Brian Blaser1,000,0008,965,82201,274,50011,255,782
17Illumina, Inc.2025Jacob Thaysen1,000,0008,763,12201,155,00011,018,895
18Guardant Health, Inc.2025AmirAli Talasaz18,647,709008,661,227
19Bio-Techne Corporation2025Kim Kelderman936,0003,929,9421,932,8481,318,9178,151,181
20Bio-Rad Laboratories, Inc.2025Norman Schwartz1,089,8774,856,5741,458,975562,0887,995,841
21DexCom, Inc.2025Jacob Leach768,9625,936,06201,164,7807,985,960
2210x Genomics, Inc.2025Serge Saxonov674,2505,020,2690634,7256,329,244
23Penumbra, Inc.2025Adam Elsesser850,000000851,621

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Exact Sciences47%PSU 60 · RSU 40NoAon
10x Genomics, Inc.93%PSU 60 · RSU 40Yes — 3-year Relative TSRAlpine Rewards LLC
Agilent Technologies, Inc.not disclosedPSU 60 · Options 20 · RSU 20NoSemler Brossy
Align Technology, Inc.58.1%MSU 70 · RSU 30Yes — Relative Total Stockholder Return (TSR) vs. Nasdaq Composite IndexCompensia, Inc.
Alnylam Pharmaceuticals, Inc.200%PSU 50 · RSU 25 · Option 25NoPay Governance
Bio-Rad Laboratories, Inc.not disclosednot disclosednot disclosedCompensia, Inc.
Bio-Techne Corporation128.1%PSU 50 · Options 25 · RSU 25NoAon
BioMarin Pharmaceutical Inc.130%PSU 66 · RSU 21 · Options 13Yes — Relative TSRAon Human Capital Solutions
DexCom, Inc.not disclosednot disclosedYes — Relative TSR Performance MetricAon Hewitt Consulting Company
Edwards Lifesciences Corporation127%Options 50 · PSU 25 · RSU 25NoSemler Brossy Consulting Group
Guardant Health, Inc.140%PSU 50 · RSU 50NoAon
Hologic, Inc.109%PSU 50 · RSU 25 · Option 25NoPearl Meyer & Partners, LLC
Horizon Therapeutics Public Ltd Co100%RSU 50 · PSU 50Yes — Relative TSRAon
IDEXX Laboratories, Inc.140%Options 50 · PSU 50NoFarient
Illumina, Inc.1155%not disclosedYes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology IndexAon (Aon's Human Capital Practice, a division of Aon, plc)
Incyte Corporation138.6%Performance Shares 60 · RSU 40Yes — relative total shareholder return (TSR)Aon
Insulet Corporation195.8%PSU 60 · RSU 20 · Options 20NoPearl Meyer & Partners, LLC
Masimo Corporationnot disclosednot disclosednot disclosedFW Cook
Natera, Inc.131.1%PSU 50 · RSU 50NoAon
Penumbra, Inc.not disclosednot disclosedNoCompensia
Quidel Corporation127%PSU 60 · RSU 40Yes — Total Shareholder Return (TSR)Compensia
ResMed Inc.not disclosedPSU 50 · RSU 25 · Options 25Yes — Relative TSRFW Cook
Seagen, Inc.130%RSU 60 · PSU 40Yes — Relative TSRAon

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Exact Sciences in fiscal 2024?
As disclosed, Kevin Conroy (Chairman, President and Chief Executive Officer) was the highest-paid executive at Exact Sciences in fiscal 2024, with total compensation of $15,539,378.
How does Exact Sciences's chief executive pay compare to its disclosed peer group?
As disclosed, Kevin Conroy's total compensation ranked at the 59th percentile of Exact Sciences's disclosed peer group.
What is Exact Sciences's CEO-to-median employee pay ratio?
As disclosed, Exact Sciences's CEO-to-median employee pay ratio was 109:1.
How did shareholders vote on Exact Sciences's executive compensation?
As disclosed, 93.58% of shareholders supported Exact Sciences's executive compensation in the latest say-on-pay vote.
How much does Exact Sciences spend in total on board compensation for fiscal 2024?
As disclosed, Exact Sciences reported total board compensation of $3,227,291 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Kevin ConroyDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation”. As printed: 15,539,378. Filing ↗machine: span 1077855–1077865
2Section 01, Aaron BloomerDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation”. As printed: 7,186,788. Filing ↗machine: span 1088764–1088773
3Section 01, Jacob OrvilleDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation”. As printed: 4,433,192. Filing ↗machine: span 1105395–1105404
4Section 01, Brian BaranickDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation”. As printed: 4,399,668. Filing ↗machine: span 1114796–1114805
5Section 01, Everett CunninghamDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation”. As printed: 4,141,654. Filing ↗machine: span 1132827–1132836
6Section 01, Jeffrey ElliottDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation”. As printed: 3,221,441. Filing ↗machine: span 1094888–1094897
7Section 01, Sarah CondellaDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation”. As printed: 2,645,555. Filing ↗machine: span 1123056–1123065
8Section 03, Brian Baranick PSUDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1212305–1212314
9Section 03, Sarah Condella PSUDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1223017–1223024
10Section 03, Kevin Conroy PSUDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1165648–1165657
11Section 03, Jacob Orville PSUDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1198548–1198557
12Section 03, Jeffrey Elliott RSUDEF 14A2025-04-290001124140-25-000034Section “Grants of Plan-Based Awards in 2024” · grants of plan-based awards table. Filing ↗machine: t209 · r10 · c18 · span 1185620–1185627
13Section 03, Aaron Bloomer RSUDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1175907–1175914
14Section 03, Aaron Bloomer RSUDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1172765–1172774
15Section 03, Sarah Condella RSUDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1219876–1219883
16Section 03, Everett Cunningham RSUDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1230581–1230590
17Section 03, Jacob Orville RSUDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1192712–1192721
18Section 03, Aaron Bloomer PSUDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1178599–1178608
19Section 03, Brian Baranick RSUDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1205569–1205578
20Section 03, Brian Baranick RSUDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1209186–1209195
21Section 03, Kevin Conroy RSUDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1162444–1162453
22Section 03, Everett Cunningham PSUDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1233726–1233735
23Section 03, Jacob Orville RSUDEF 14A2025-04-290001124140-25-000034Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1195854–1195863
24Section 07, pay ratioDEF 14A2025-04-290001124140-25-000034Section “CEO Pay Ratio”. As printed: 109 : 1. Filing ↗
25Section 08, Michael BarberDEF 14A2025-04-290001124140-25-000034Section “Director Compensation”. As printed: 673,683. Filing ↗machine: span 600556–600807
26Section 08, James DoyleDEF 14A2025-04-290001124140-25-000034Section “Director Compensation”. As printed: 381,392. Filing ↗machine: span 606269–606706
27Section 08, Paul ClancyDEF 14A2025-04-290001124140-25-000034Section “Director Compensation”. As printed: 356,392. Filing ↗machine: span 602334–602771
28Section 08, Daniel LevangieDEF 14A2025-04-290001124140-25-000034Section “Director Compensation”. As printed: 346,392. Filing ↗machine: span 610390–610827
29Section 08, Katherine ZanottiDEF 14A2025-04-290001124140-25-000034Section “Director Compensation”. As printed: 343,892. Filing ↗machine: span 623524–624048
30Section 08, Kathleen SebeliusDEF 14A2025-04-290001124140-25-000034Section “Director Compensation”. As printed: 341,392. Filing ↗machine: span 619142–619579
31Section 08, Shacey PetrovicDEF 14A2025-04-290001124140-25-000034Section “Director Compensation”. As printed: 338,892. Filing ↗machine: span 614513–614950
32Section 08, D. Scott CowardDEF 14A2025-04-290001124140-25-000034Section “Director Compensation”. As printed: 333,892. Filing ↗machine: span 604303–604740
33Section 08, Timothy ScannellDEF 14A2025-04-290001124140-25-000034Section “Director Compensation”. As printed: 111,364. Filing ↗machine: span 615994–616535
34Section 08, Freda Lewis-HallDEF 14A2025-04-290001124140-25-000034Section “Director Compensation”. As printed: 0. Filing ↗
35Section 08, Kimberly PopovitsDEF 14A2025-04-290001124140-25-000034Section “Director Compensation”. As printed: 0. Filing ↗
36Section 08, Kevin ConroyDEF 14A2025-04-290001124140-25-000034Section “Director Compensation”. As printed: 0. Filing ↗
37Section 08, Leslie TriggDEF 14A2025-04-290001124140-25-000034Section “Director Compensation”. As printed: 0. Filing ↗
38Section 08, Pierre JacquetDEF 14A2025-04-290001124140-25-000034Section “Director Compensation”. As printed: 0. Filing ↗
39Section 02, D. Scott Coward 2025-06-12Form 42025-06-160000950170-25-086883Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Daniel Levangie 2025-06-12Form 42025-06-160000950170-25-086884Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Shacey Petrovic 2025-06-12Form 42025-06-160000950170-25-086886Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Leslie Trigg 2025-06-12Form 42025-06-160000950170-25-086887Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Kimberly Popovits 2025-06-12Form 42025-06-160000950170-25-086888Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Michael Barber 2025-06-12Form 42025-06-160000950170-25-086890Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, James Doyle 2025-06-12Form 42025-06-160000950170-25-086891Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Katherine Zanotti 2025-06-12Form 42025-06-160000950170-25-086885Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Paul Clancy 2025-06-12Form 42025-06-160000950170-25-086889Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Katherine Zanotti 2025-06-13Form 42025-06-160000950170-25-086885Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Brian Baranick 2025-08-05Form 42025-08-070000950170-25-105255Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Brian Baranick 2025-08-05Form 42025-08-070000950170-25-105255Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Jacob Orville 2025-08-05Form 42025-08-070000950170-25-105256Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Brian Baranick 2025-08-05Form 42025-08-070000950170-25-105255Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Jacob Orville 2025-08-05Form 42025-08-070000950170-25-105256Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Jacob Orville 2025-08-05Form 42025-08-070000950170-25-105256Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, James Doyle 2025-08-13Form 42025-08-140000950170-25-108967Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, James Herriott 2025-10-09Form 42025-10-100001193125-25-237239Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, James Doyle 2025-10-09Form 42025-10-100001193125-25-237233Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Katherine Zanotti 2025-10-24Form 42025-10-270001193125-25-251958Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Brian Baranick 2025-11-04Form 42025-11-060001193125-25-270166Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, James Herriott 2025-11-04Form 42025-11-060001193125-25-270168Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, James Herriott 2025-11-19Form 42025-11-210001193125-25-291649Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Jacob Orville 2025-11-19Form 42025-11-210001193125-25-291651Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Aaron Bloomer 2025-12-23Form 42025-12-300001193125-25-337151Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Aaron Bloomer 2025-12-23Form 42025-12-300001193125-25-337151Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Aaron Bloomer 2025-12-23Form 42025-12-300001193125-25-337151Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Aaron Bloomer 2025-12-23Form 42025-12-300001193125-25-337151Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Aaron Bloomer 2025-12-23Form 42025-12-300001193125-25-337151Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Kevin Conroy 2025-12-23Form 42025-12-300001193125-25-337153Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Kevin Conroy 2025-12-23Form 42025-12-300001193125-25-337153Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Kevin Conroy 2025-12-23Form 42025-12-300001193125-25-337153Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Kevin Conroy 2025-12-23Form 42025-12-300001193125-25-337153Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Kevin Conroy 2025-12-23Form 42025-12-300001193125-25-337153Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Sarah Condella 2025-12-23Form 42025-12-300001193125-25-337154Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Sarah Condella 2025-12-23Form 42025-12-300001193125-25-337154Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Sarah Condella 2025-12-23Form 42025-12-300001193125-25-337154Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, James Herriott 2025-12-23Form 42025-12-300001193125-25-337152Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Sarah Condella 2025-12-23Form 42025-12-300001193125-25-337154Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Sarah Condella 2025-12-23Form 42025-12-300001193125-25-337154Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, Jacob Orville 2025-12-23Form 42025-12-300001193125-25-337156Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Brian Baranick 2025-12-23Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Sarah Condella 2025-12-23Form 42025-12-300001193125-25-337154Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Sarah Condella 2025-12-23Form 42025-12-300001193125-25-337154Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Sarah Condella 2025-12-23Form 42025-12-300001193125-25-337154Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Sarah Condella 2025-12-23Form 42025-12-300001193125-25-337154Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Sarah Condella 2025-12-23Form 42025-12-300001193125-25-337154Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Sarah Condella 2025-12-23Form 42025-12-300001193125-25-337154Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Sarah Condella 2025-12-23Form 42025-12-300001193125-25-337154Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Sarah Condella 2025-12-23Form 42025-12-300001193125-25-337154Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Sarah Condella 2025-12-23Form 42025-12-300001193125-25-337154Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Sarah Condella 2025-12-23Form 42025-12-300001193125-25-337154Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, Sarah Condella 2025-12-23Form 42025-12-300001193125-25-337154Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Kevin Conroy 2025-12-23Form 42025-12-300001193125-25-337153Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Aaron Bloomer 2025-12-23Form 42025-12-300001193125-25-337151Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Brian Baranick 2025-12-24Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Brian Baranick 2025-12-24Form 42025-12-300001193125-25-337155Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, Aaron Bloomer 2026-02-25Form 42026-02-270001193125-26-082834Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, Kevin Conroy 2026-02-25Form 42026-02-270001193125-26-082828Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, Kevin Conroy 2026-02-25Form 42026-02-270001193125-26-082828Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, Kevin Conroy 2026-02-25Form 42026-02-270001193125-26-082828Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, James Herriott 2026-02-25Form 42026-02-270001193125-26-082829Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, Jacob Orville 2026-02-25Form 42026-02-270001193125-26-082839Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, Brian Baranick 2026-02-25Form 42026-02-270001193125-26-082836Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, Sarah Condella 2026-02-25Form 42026-02-270001193125-26-082832Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, Sarah Condella 2026-02-27Form 42026-03-030001193125-26-089302Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, Sarah Condella 2026-02-27Form 42026-03-030001193125-26-089302Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Kevin Conroy 2026-02-27Form 42026-03-030001193125-26-089303Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Kevin Conroy 2026-02-27Form 42026-03-030001193125-26-089303Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Kevin Conroy 2026-02-27Form 42026-03-030001193125-26-089303Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, Kevin Conroy 2026-02-27Form 42026-03-030001193125-26-089303Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, Kevin Conroy 2026-02-27Form 42026-03-030001193125-26-089303Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, Kevin Conroy 2026-02-27Form 42026-03-030001193125-26-089303Insider equity transaction reported since the proxy statement. Filing ↗
172Section 02, Sarah Condella 2026-02-27Form 42026-03-030001193125-26-089302Insider equity transaction reported since the proxy statement. Filing ↗
173Section 02, Kevin Conroy 2026-02-27Form 42026-03-030001193125-26-089303Insider equity transaction reported since the proxy statement. Filing ↗
174Section 02, Kevin Conroy 2026-02-27Form 42026-03-030001193125-26-089303Insider equity transaction reported since the proxy statement. Filing ↗
175Section 02, Kevin Conroy 2026-02-27Form 42026-03-030001193125-26-089303Insider equity transaction reported since the proxy statement. Filing ↗
176Section 02, Michael Barber 2026-03-23Form 42026-03-230001193125-26-118742Insider equity transaction reported since the proxy statement. Filing ↗
177Section 02, Paul Clancy 2026-03-23Form 42026-03-230001193125-26-118743Insider equity transaction reported since the proxy statement. Filing ↗
178Section 02, Paul Clancy 2026-03-23Form 42026-03-230001193125-26-118743Insider equity transaction reported since the proxy statement. Filing ↗
179Section 02, James Doyle 2026-03-23Form 42026-03-230001193125-26-118744Insider equity transaction reported since the proxy statement. Filing ↗
180Section 02, James Doyle 2026-03-23Form 42026-03-230001193125-26-118744Insider equity transaction reported since the proxy statement. Filing ↗
181Section 02, Kimberly Popovits 2026-03-23Form 42026-03-230001193125-26-118745Insider equity transaction reported since the proxy statement. Filing ↗
182Section 02, Katherine Zanotti 2026-03-23Form 42026-03-230001193125-26-118747Insider equity transaction reported since the proxy statement. Filing ↗
183Section 02, Katherine Zanotti 2026-03-23Form 42026-03-230001193125-26-118747Insider equity transaction reported since the proxy statement. Filing ↗
184Section 02, Shacey Petrovic 2026-03-23Form 42026-03-230001193125-26-118748Insider equity transaction reported since the proxy statement. Filing ↗
185Section 02, D. Scott Coward 2026-03-23Form 42026-03-230001193125-26-118752Insider equity transaction reported since the proxy statement. Filing ↗
186Section 02, D. Scott Coward 2026-03-23Form 42026-03-230001193125-26-118752Insider equity transaction reported since the proxy statement. Filing ↗
187Section 02, D. Scott Coward 2026-03-23Form 42026-03-230001193125-26-118752Insider equity transaction reported since the proxy statement. Filing ↗
188Section 02, Jacob Orville 2026-03-23Form 42026-03-230001193125-26-118754Insider equity transaction reported since the proxy statement. Filing ↗
189Section 02, Jacob Orville 2026-03-23Form 42026-03-230001193125-26-118754Insider equity transaction reported since the proxy statement. Filing ↗
190Section 02, Jacob Orville 2026-03-23Form 42026-03-230001193125-26-118754Insider equity transaction reported since the proxy statement. Filing ↗
191Section 02, Kevin Conroy 2026-03-23Form 42026-03-230001193125-26-118755Insider equity transaction reported since the proxy statement. Filing ↗
192Section 02, Kevin Conroy 2026-03-23Form 42026-03-230001193125-26-118755Insider equity transaction reported since the proxy statement. Filing ↗
193Section 02, Kevin Conroy 2026-03-23Form 42026-03-230001193125-26-118755Insider equity transaction reported since the proxy statement. Filing ↗
194Section 02, Kevin Conroy 2026-03-23Form 42026-03-230001193125-26-118755Insider equity transaction reported since the proxy statement. Filing ↗
195Section 02, Kevin Conroy 2026-03-23Form 42026-03-230001193125-26-118755Insider equity transaction reported since the proxy statement. Filing ↗
196Section 02, Kevin Conroy 2026-03-23Form 42026-03-230001193125-26-118755Insider equity transaction reported since the proxy statement. Filing ↗
197Section 02, Kevin Conroy 2026-03-23Form 42026-03-230001193125-26-118755Insider equity transaction reported since the proxy statement. Filing ↗
198Section 02, Kevin Conroy 2026-03-23Form 42026-03-230001193125-26-118755Insider equity transaction reported since the proxy statement. Filing ↗
199Section 02, Kevin Conroy 2026-03-23Form 42026-03-230001193125-26-118755Insider equity transaction reported since the proxy statement. Filing ↗
200Section 02, Sarah Condella 2026-03-23Form 42026-03-230001193125-26-118758Insider equity transaction reported since the proxy statement. Filing ↗
201Section 02, Sarah Condella 2026-03-23Form 42026-03-230001193125-26-118758Insider equity transaction reported since the proxy statement. Filing ↗
202Section 02, Aaron Bloomer 2026-03-23Form 42026-03-230001193125-26-118759Insider equity transaction reported since the proxy statement. Filing ↗
203Section 02, Aaron Bloomer 2026-03-23Form 42026-03-230001193125-26-118759Insider equity transaction reported since the proxy statement. Filing ↗
204Section 02, Aaron Bloomer 2026-03-23Form 42026-03-230001193125-26-118759Insider equity transaction reported since the proxy statement. Filing ↗
205Section 02, Aaron Bloomer 2026-03-23Form 42026-03-230001193125-26-118759Insider equity transaction reported since the proxy statement. Filing ↗
206Section 02, James Herriott 2026-03-23Form 42026-03-230001193125-26-118762Insider equity transaction reported since the proxy statement. Filing ↗
207Section 02, James Herriott 2026-03-23Form 42026-03-230001193125-26-118762Insider equity transaction reported since the proxy statement. Filing ↗
208Section 02, James Herriott 2026-03-23Form 42026-03-230001193125-26-118762Insider equity transaction reported since the proxy statement. Filing ↗
209Section 02, James Herriott 2026-03-23Form 42026-03-230001193125-26-118762Insider equity transaction reported since the proxy statement. Filing ↗
210Section 02, Brian Baranick 2026-03-23Form 42026-03-230001193125-26-118765Insider equity transaction reported since the proxy statement. Filing ↗
211Section 02, Brian Baranick 2026-03-23Form 42026-03-230001193125-26-118765Insider equity transaction reported since the proxy statement. Filing ↗
212Section 02, Brian Baranick 2026-03-23Form 42026-03-230001193125-26-118765Insider equity transaction reported since the proxy statement. Filing ↗
213Section 02, Aaron Bloomer 2026-03-23Form 42026-03-230001193125-26-118759Insider equity transaction reported since the proxy statement. Filing ↗
214Section 02, Leslie Trigg 2026-03-23Form 42026-03-230001193125-26-118740Insider equity transaction reported since the proxy statement. Filing ↗
215Section 02, Shacey Petrovic 2026-03-23Form 42026-03-230001193125-26-118748Insider equity transaction reported since the proxy statement. Filing ↗
216Section 02, D. Scott Coward 2026-03-23Form 42026-03-230001193125-26-118752Insider equity transaction reported since the proxy statement. Filing ↗
217Section 02, D. Scott Coward 2026-03-23Form 42026-03-230001193125-26-118752Insider equity transaction reported since the proxy statement. Filing ↗
218Section 02, Jacob Orville 2026-03-23Form 42026-03-230001193125-26-118754Insider equity transaction reported since the proxy statement. Filing ↗
219Section 02, Sarah Condella 2026-03-23Form 42026-03-230001193125-26-118758Insider equity transaction reported since the proxy statement. Filing ↗
220Section 02, Sarah Condella 2026-03-23Form 42026-03-230001193125-26-118758Insider equity transaction reported since the proxy statement. Filing ↗
221Section 02, James Herriott 2026-03-23Form 42026-03-230001193125-26-118762Insider equity transaction reported since the proxy statement. Filing ↗
222Section 02, Jacob Orville 2026-03-23Form 42026-03-230001193125-26-118754Insider equity transaction reported since the proxy statement. Filing ↗
223Section 02, Brian Baranick 2026-03-23Form 42026-03-230001193125-26-118765Insider equity transaction reported since the proxy statement. Filing ↗
224Section 02, Michael Barber 2026-03-23Form 42026-03-230001193125-26-118742Insider equity transaction reported since the proxy statement. Filing ↗
225Section 02, Leslie Trigg 2026-03-23Form 42026-03-230001193125-26-118740Insider equity transaction reported since the proxy statement. Filing ↗
226Section 02, Sarah Condella 2026-03-23Form 42026-03-230001193125-26-118758Insider equity transaction reported since the proxy statement. Filing ↗
227Section 02, Sarah Condella 2026-03-23Form 42026-03-230001193125-26-118758Insider equity transaction reported since the proxy statement. Filing ↗
228Section 02, Sarah Condella 2026-03-23Form 42026-03-230001193125-26-118758Insider equity transaction reported since the proxy statement. Filing ↗
229Section 02, Sarah Condella 2026-03-23Form 42026-03-230001193125-26-118758Insider equity transaction reported since the proxy statement. Filing ↗
230Section 02, Kimberly Popovits 2026-03-23Form 42026-03-230001193125-26-118745Insider equity transaction reported since the proxy statement. Filing ↗
231Section 02, Kevin Conroy 2026-03-23Form 42026-03-230001193125-26-118755Insider equity transaction reported since the proxy statement. Filing ↗
232Section 02, Kevin Conroy 2026-03-23Form 42026-03-230001193125-26-118755Insider equity transaction reported since the proxy statement. Filing ↗
233Section 02, Kevin Conroy 2026-03-23Form 42026-03-230001193125-26-118755Insider equity transaction reported since the proxy statement. Filing ↗
234Section 02, Kevin Conroy 2026-03-23Form 42026-03-230001193125-26-118755Insider equity transaction reported since the proxy statement. Filing ↗
235Section 02, Kevin Conroy 2026-03-23Form 42026-03-230001193125-26-118755Insider equity transaction reported since the proxy statement. Filing ↗
236Section 02, D. Scott Coward 2026-03-23Form 42026-03-230001193125-26-118752Insider equity transaction reported since the proxy statement. Filing ↗
237Section 02, Michael Barber 2026-03-23Form 42026-03-230001193125-26-118742Insider equity transaction reported since the proxy statement. Filing ↗
238Section 02, Shacey Petrovic 2026-03-23Form 42026-03-230001193125-26-118748Insider equity transaction reported since the proxy statement. Filing ↗
239Section 06, 2025 voteForm 8-K2025-06-160001124140-25-000046Item 5.07 · say-on-pay result. As reported: 93.58% (votes for as printed: 140,371,292). Filing ↗
240Section 06, 2024 voteForm 8-K2024-06-170001124140-24-000054Item 5.07 · say-on-pay result. As reported: 91.53% (votes for as printed: 131,505,677). Filing ↗
241Section 06, 2023 voteForm 8-K2023-06-120001124140-23-000054Item 5.07 · say-on-pay result. As reported: 90.64% (votes for as printed: 125,242,817). Filing ↗
242Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
243Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
244Section 09b board cost (computed)Computed——Cash 767,500 + equity 2,459,791 + all other 0 = 3,227,291, summed across the director compensation table rows.machine: formula: Σ = 3,227,291
245Seagen, Inc., Section 10b CEO totalDEF 14A2023-04-180001060736-23-000019CEO total compensation as printed in Seagen, Inc.'s own proxy. As printed: 57,460,546. Filing ↗machine: r2 · c36 · span 1339226–1339236
246Incyte Corporation, Section 10b CEO totalDEF 14A2026-04-280000879169-26-000031CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827
247BioMarin Pharmaceutical Inc., Section 10b CEO totalDEF 14A2026-04-210001628280-26-026290CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915
248Horizon Therapeutics Public Ltd Co, Section 10b CEO totalDEF 14A2023-06-300001193125-23-180318CEO total compensation as printed in Horizon Therapeutics Public Ltd Co's own proxy. As printed: 20,103,869. Filing ↗machine: span 746414–746424
249Masimo Corporation, Section 10b CEO total10-K2026-05-010001104659-26-054180CEO total compensation as printed in Masimo Corporation's own proxy. As printed: 19,797,140. Filing ↗machine: r4 · c22 · span 477159–477169
250Align Technology, Inc., Section 10b CEO totalDEF 14A2026-04-070001097149-26-000023CEO total compensation as printed in Align Technology, Inc.'s own proxy. As printed: 19,193,988. Filing ↗machine: r2 · c42 · span 933168–933178
251Insulet Corporation, Section 10b CEO totalDEF 14A2026-04-060001140361-26-013333CEO total compensation as printed in Insulet Corporation's own proxy. As printed: 18,858,968. Filing ↗machine: t218 · r3 · c25 · span 1028076–1028087
252Edwards Lifesciences Corporation, Section 10b CEO totalDEF 14A2026-03-260001099800-26-000015CEO total compensation as printed in Edwards Lifesciences Corporation's own proxy. As printed: 17,454,255. Filing ↗machine: r2 · c27 · span 965441–965451
253ResMed Inc., Section 10b CEO totalDEF 14A2026-10-010000943819-26-000080CEO total compensation as printed in ResMed Inc.'s own proxy. As printed: 16,201,649. Filing ↗machine: span 1267106–1267116
254Hologic, Inc., Section 10b CEO totalDEF 14A2025-01-160001140361-25-001287CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674
255Exact Sciences (subject), Section 10b CEO totalDEF 14A2025-04-290001124140-25-000034CEO total compensation as printed in Exact Sciences's own proxy. As printed: 15,539,378. Filing ↗machine: span 1077855–1077865
256Natera, Inc., Section 10b CEO totalDEF 14A2026-04-230001104659-26-047770CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878
257Alnylam Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-060001628280-26-023923CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701
258IDEXX Laboratories, Inc., Section 10b CEO totalDEF 14A2026-03-270000874716-26-000064CEO total compensation as printed in IDEXX Laboratories, Inc.'s own proxy. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018
259Agilent Technologies, Inc., Section 10b CEO totalDEF 14A2026-02-060001193125-26-040286CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992
260Quidel Corporation, Section 10b CEO totalDEF 14A2026-04-270001906324-26-000018CEO total compensation as printed in Quidel Corporation's own proxy. As printed: 11,255,782. Filing ↗machine: r4 · c24 · span 760612–760622
261Illumina, Inc., Section 10b CEO totalDEF 14A2026-04-090001193125-26-149669CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536
262Guardant Health, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-187403CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. Filing ↗machine: r7 · c31 · span 773149–773158
263Bio-Techne Corporation, Section 10b CEO totalDEF 14A2025-09-190001308179-25-000599CEO total compensation as printed in Bio-Techne Corporation's own proxy. As printed: 8,151,181. Filing ↗machine: span 792074–792083
264Bio-Rad Laboratories, Inc., Section 10b CEO totalDEF 14A2026-03-250000012208-26-000020CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. Filing ↗machine: r2 · c24 · span 654200–654209
265DexCom, Inc., Section 10b CEO totalDEF 14A2026-04-150001093557-26-000061CEO total compensation as printed in DexCom, Inc.'s own proxy. As printed: 7,985,960. Filing ↗machine: span 940364–940373
26610x Genomics, Inc., Section 10b CEO totalDEF 14A2026-04-240001628280-26-027201CEO total compensation as printed in 10x Genomics, Inc.'s own proxy. As printed: 6,329,244. Filing ↗machine: r3 · c48 · span 583283–583292
267Penumbra, Inc., Section 10b CEO totalDEF 14A2026-04-290001321732-26-000010CEO total compensation as printed in Penumbra, Inc.'s own proxy. As printed: 851,621. Filing ↗machine: span 424797–424804
268Section 10a, Edwards Lifesciences Corporation reciprocityDEF 14A—0001099800-26-000015Edwards Lifesciences Corporation's most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗
269Section 10a, Seagen, Inc. reciprocityDEF 14A—0001060736-23-000019Seagen, Inc. names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗
270Section 10a, Horizon Therapeutics Public Ltd Co reciprocityDEF 14A—0001193125-23-180318Horizon Therapeutics Public Ltd Co's most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗
271Section 10a, Penumbra, Inc. reciprocityDEF 14A—0001321732-26-000010Penumbra, Inc.'s most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗
272Section 10a, Quidel Corporation reciprocityDEF 14A—0001906324-26-000018Quidel Corporation names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗
273Section 10a, 10x Genomics, Inc. reciprocityDEF 14A—0001628280-26-02720110x Genomics, Inc. names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗
274Section 10a, Agilent Technologies, Inc. reciprocityDEF 14A—0001193125-26-040286Agilent Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗
275Section 10a, Bio-Techne Corporation reciprocityDEF 14A—0001308179-25-000599Bio-Techne Corporation names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗
276Section 10a, Guardant Health, Inc. reciprocityDEF 14A—0001193125-26-187403Guardant Health, Inc. names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗
277Section 10a, DexCom, Inc. reciprocityDEF 14A—0001093557-26-000061DexCom, Inc. names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗
278Section 10a, Hologic, Inc. reciprocityDEF 14A—0001140361-25-001287Hologic, Inc.'s most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗
279Section 10a, IDEXX Laboratories, Inc. reciprocityDEF 14A—0000874716-26-000064IDEXX Laboratories, Inc.'s most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗
280Section 10a, Insulet Corporation reciprocityDEF 14A—0001140361-26-013333Insulet Corporation names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗
281Section 10a, Alnylam Pharmaceuticals, Inc. reciprocityDEF 14A—0001628280-26-023923Alnylam Pharmaceuticals, Inc. names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗
282Section 10a, BioMarin Pharmaceutical Inc. reciprocityDEF 14A—0001628280-26-026290BioMarin Pharmaceutical Inc.'s most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗
283Section 10a, Natera, Inc. reciprocityDEF 14A—0001104659-26-047770Natera, Inc. names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗
284Section 10a, Align Technology, Inc. reciprocityDEF 14A—0001097149-26-000023Align Technology, Inc.'s most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗
285Section 10a, Masimo Corporation reciprocityDEF 14A—0001104659-26-054180Masimo Corporation's most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗
286Section 10a, ResMed Inc. reciprocityDEF 14A—0000943819-26-000080ResMed Inc.'s most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.